跳到內容

跳到副選單

耶和華見證人

中文繁體(國語)

兒童乙型地中海貧血

重度乙型地中海貧血——經由藥物誘導體內胎兒血紅蛋白的合成

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia.

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

出處‎: Iran J Blood Cancer 2009;1(4):147-50.

檢索‎: IMEMR 107228

http://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin.

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

出處‎: Pediatr Hematol Oncol 1997;14(3):285-7.

檢索‎: PubMed 9185215

http://www.ncbi.nlm.nih.gov/pubmed/9185215

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

出處‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

檢索‎: PubMed 23389500

DOI碼‎: 10.1097/MPH.0b013e31827e8662

http://www.ncbi.nlm.nih.gov/pubmed/23389500

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

出處‎: Int J Hematol 2012;95(1):51-6.

檢索‎: PubMed 22180324

DOI碼‎: 10.1007/s12185-011-0985-6

http://www.ncbi.nlm.nih.gov/pubmed/22180324

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

出處‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

檢索‎: PubMed 21602718

DOI碼‎: 10.1097/MPH.0b013e31821b0770

http://www.ncbi.nlm.nih.gov/pubmed/21602718

Fetal globin gene inducers: novel agents and new potential.

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

出處‎: Ann N Y Acad Sci 2010;1202:158-64.

檢索‎: PubMed 20712788

DOI碼‎: 10.1111/j.1749-6632.2010.05593.x

http://www.ncbi.nlm.nih.gov/pubmed/20712788

Hydroxyurea therapy in 49 patients with major beta-thalassemia.

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

出處‎: Arch Iran Med 2009;12(3):295-7.

檢索‎: PubMed 19400608

http://www.ncbi.nlm.nih.gov/pubmed/19400608

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

出處‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

檢索‎: PubMed 17984691

http://www.ncbi.nlm.nih.gov/pubmed/17984691

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

出處‎: Transfusion 2007;47(10):1830-6.

檢索‎: PubMed 17880608

http://www.ncbi.nlm.nih.gov/pubmed/17880608

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

出處‎: Haematologica 2004;89(10):1172-8.

檢索‎: PubMed 15477200

http://www.ncbi.nlm.nih.gov/pubmed/15477200

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

出處‎: Blood 2003;102(4):1529-30.

檢索‎: PubMed 12702505

http://www.ncbi.nlm.nih.gov/pubmed/12702505

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ߺ thalassemia.

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

出處‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

檢索‎: PubMed 12468925

http://www.ncbi.nlm.nih.gov/pubmed/12468925


JW.ORG​網站​內​的​醫療​資訊​主要​是​提供​給​醫生​及​醫療人員​參考,而​不​是​要​提供​診斷​建議​或​推薦​某​種​醫療​方法,也​不​是​要​取代​專業​的​醫療​護理。網站​上​引用​的​許多​醫學​文章​都​不​是​耶和華見證人​出版​的,但​當​中​提​到​了​許多​替代​輸​血​的​療法,這些​醫療​策略​很​值得​醫生​參考。每​一​個​專業​醫療人員​都​有​責任​經常​吸收​最​新​的​醫療​資訊,討論​最​適合​病人​的​醫療​方法。他們​也​要​根據​病人​的​病情、意願、價值觀​和​信仰​來​協助​病人​選擇​最佳​的​醫療​方式。本​網站​所​提供​的​醫療​策略​不​一定​適用​於​每​一​個​病人。

給​病人​的​建議:當​你​感到​身體​不適,要​立刻​尋求​醫生​的​幫助,也​要​聽取​醫生​以及​其他​專業​醫療人員​的​建議。

使用​本​網站​即​表示​你​接受​本使用​條款的​全部​內容。